

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 950)

GRANT OF SHARE OPTIONS

The Board announces that on 15 April 2020, the Company has granted Options to subscribe for a total of 8,814,000 Shares under the Share Option Scheme.

This announcement is made pursuant to rule 17.06A of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited.

The board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), announces that on 15 April 2020, the Company has granted share options (the “**Options**”) to subscribe for a total of 8,814,000 ordinary shares of the Company (the “**Shares**”) under the share option scheme adopted on 10 May 2012 (the “**Share Option Scheme**”). The following are the details of the grant of Options:

Date of grant	15 April 2020	
Exercise price of the Options	HK\$3.648 per Share	
Number of Options granted	8,814,000 Shares	
Closing price of the Shares on the date of grant	HK\$3.500 per Share	
Average closing price of the Shares for the five business days immediately preceding the date of grant	HK\$3.648 per Share	
Details of grantees		
Directors of the Company		
<u>Name</u>	<u>Position</u>	<u>Number of Options</u>
Lee Siu Fong	Chairman	588,000
Leelalertsuphakun Wane	Managing Director	588,000
Li Xiaoyi	Chief Executive Officer	588,000
Total Options granted to directors of the Company		1,764,000
Total Options granted to employees of the Group		7,050,000
Total Options granted		8,814,000

Validity period of the Options

Directors of the Company:

- (i) 50% of the Options are exercisable from 15 October 2020 to 14 April 2030; and
- (ii) 50% of the Options are exercisable from 15 July 2021 to 14 April 2030.

Employees of the Group:

- (i) 50% of the Options are exercisable from 15 October 2021 to 14 April 2030; and
- (ii) 50% of the Options are exercisable from 15 April 2023 to 14 April 2030.

The granting of the Options to the directors of the Company were approved by the independent non-executive directors of the Company.

Save as disclosed above, none of the grantees of the Options is a director, chief executive or substantial shareholder of the Company, or any of their respective associates (as defined under the Listing Rules) as at the date of this announcement.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 15 April 2020

** For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.